NASDAQ:KYMR Kymera Therapeutics (KYMR) Stock Price, News & Analysis $114.84 +4.08 (+3.68%) Closing price 10/26/2026 04:00 PM EasternExtended Trading$112.50 -2.34 (-2.04%) As of 10/26/2026 07:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Kymera Therapeutics Stock (NASDAQ:KYMR) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Kymera Therapeutics alerts:Sign Up Key Stats Today's Range$110.31▼$115.2250-Day Range$104.78▼$127.3152-Week Range$55.66▼$130.05Volume438,504 shsAverage Volume839,585 shsMarket Capitalization$9.55 billionP/E RatioN/ADividend YieldN/APrice Target$134.68Consensus RatingModerate Buy Company Overview Kymera Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing medicines that selectively eliminate disease-causing proteins through targeted protein degradation. Its approach is designed to use the cell’s natural protein-disposal system to remove proteins that may be difficult to address with conventional drug modalities. The company’s research and development programs have targeted a range of disease areas, including immune-mediated and inflammatory conditions, cancer, and other serious illnesses. Kymera’s pipeline has included degraders directed at proteins such as IRAK4, STAT3, and STAT6, with candidates evaluated in clinical or preclinical studies depending on the program. The company continues to use its proprietary platform to identify and develop additional targeted protein degraders. Founded in 2016 and headquartered in the Boston-area biotechnology hub of Massachusetts, Kymera operates as a research-focused company and has advanced its programs through collaborations and clinical development activities. Its work is intended to support the development of medicines for patients in the United States and international markets, although the company’s programs remain centered on research and development rather than a broad portfolio of marketed products.AI Generated. May Contain Errors. Read More Kymera Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks43rd Percentile Overall ScoreKYMR MarketRank™: 2.144897429235 of 5 starsKymera Therapeutics scored higher than 43% of companies evaluated by MarketBeat, and ranked 650th out of 907 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.8 / 5Analyst RatingModerate Buy Consensus RatingKymera Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.89, and is based on 1 strong buy rating, 23 buy ratings, 2 hold ratings, and 1 sell rating.Upside PotentialKymera Therapeutics has a consensus price target of $134.68, representing about 17.3% upside from its current price of $114.84.Amount of Analyst CoverageKymera Therapeutics has been the subject of 14 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Kymera Therapeutics' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Kymera Therapeutics are expected to decrease in the coming year, from ($3.85) to ($5.09) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Kymera Therapeutics is -35.44, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Kymera Therapeutics is -35.44, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioKymera Therapeutics has a P/B Ratio of 5.91. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Kymera Therapeutics' valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted13.13% of the float of Kymera Therapeutics has been sold short.Short Interest Ratio / Days to CoverKymera Therapeutics has a short interest ratio ("days to cover") of 9.96.Change versus previous monthShort interest in Kymera Therapeutics has recently decreased by 7.45%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldKymera Therapeutics does not currently pay a dividend.Dividend GrowthKymera Therapeutics does not have a long track record of dividend growth. News and Social Media0.6 / 5News Sentiment0.00 News Coverage This WeekMarketBeat has tracked 4 news articles for Kymera Therapeutics this week, compared to 7 articles on an average week.Search InterestOnly 4 people have searched for KYMR on MarketBeat in the last 30 days. This is a decrease of -60% compared to the previous 30 days.MarketBeat Follows3 people have added Kymera Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days. Company Ownership1.3 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Kymera Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $4,158,324.00 in company stock.Percentage Held by Insiders15.98% of the stock of Kymera Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsKymera Therapeutics has minimal institutional ownership at this time.Read more about Kymera Therapeutics' insider trading history. Receive KYMR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Kymera Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. KYMR Stock News HeadlinesKymera Therapeutics (KYMR) Expected to Announce Quarterly Earnings on ThursdayOctober 24 at 1:41 AM | americanbankingnews.comKymera Therapeutics to Report Third Quarter 2026 Financial Results on October 29, 2026October 22, 2026 | globenewswire.comElon Musk’s Hushed FCC Filing. Dec 8th.Elon Musk quietly filed a document with the federal government tied to artificial intelligence, one of the largest markets in the world. James Altucher, who previously flagged Nvidia in 2008 and Bitcoin in 2013, says the filing could rival Tesla, SpaceX and xAI combined. Few investors know this filing exists, but that is expected to change quickly. | Paradigm Press (Ad)SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Kymera Therapeutics, Inc. (NASDAQ: KYMR)October 12, 2026 | prnewswire.comRaymond James initiates coverage of Kymera Therapeutics with outperform ratingOctober 9, 2026 | msn.comKymera: Over-Hyped, Or Developing Next Dupixent? We'll Find Out Very SoonOctober 9, 2026 | seekingalpha.comKymera Therapeutics (NASDAQ:KYMR) CEO Nello Mainolfi Sells 30,000 Shares of StockOctober 2, 2026 | insidertrades.comKuehn Law Encourages Investors of Kymera Therapeutics, Inc. to Contact Law FirmSeptember 30, 2026 | prnewswire.comSee More Headlines KYMR Stock Analysis - Frequently Asked Questions How have KYMR shares performed this year? Kymera Therapeutics' stock was trading at $77.81 at the beginning of the year. Since then, KYMR stock has increased by 47.6% and is now trading at $114.84. How were Kymera Therapeutics' earnings last quarter? Kymera Therapeutics, Inc. (NASDAQ:KYMR) announced its quarterly earnings results on Wednesday, August, 5th. The company reported ($0.62) earnings per share for the quarter, topping the consensus estimate of ($0.71) by $0.09. The business's quarterly revenue was up 465.2% compared to the same quarter last year. Read the conference call transcript. When did Kymera Therapeutics IPO? Kymera Therapeutics (KYMR) raised $148 million in an initial public offering (IPO) on Friday, August 21st 2020. The company issued 8,684,800 shares at a price of $16.00-$18.00 per share. Morgan Stanley, BofA Securities, Cowen and Guggenheim Securities served as the underwriters for the IPO. Who are Kymera Therapeutics' major shareholders? Top institutional investors of Kymera Therapeutics include Abel Hall LLC (0.01%), Inspire Investing LLC (0.01%), NorthCrest Asset Manangement LLC and Nisa Investment Advisors LLC. Insiders that own company stock include Bros Advisors Lp Baker, Venture Fund X LP Atlas, Nello Mainolfi, Bruce Booth, Bruce N Jacobs, Bvf Partners L P/Il, Jared Gollob, Ellen Chiniara, Brian Adams, Noah Goodman, Jeremy G Chadwick, Elena Ridloff and Joanna Horobin. View institutional ownership trends. How do I buy shares of Kymera Therapeutics? Shares of KYMR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Kymera Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Kymera Therapeutics investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Kratos Defense & Security Solutions (KTOS), Rocket Lab (RKLB), Archer Aviation (ACHR), NuScale Power (SMR) and Taiwan Semiconductor Manufacturing (TSM). Company Calendar Last Earnings8/05/2026Today10/27/2026Next Earnings (Estimated)10/29/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (18m+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 KYMR's financial health is in the Green zone, according to TradeSmith. KYMR has been in this zone for over 18 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:KYMR CIK1815442 Webwww.kymeratx.com Phone(857) 285-5314FaxN/AEmployees273Year Founded2017Price Target and Rating Average Price Target for Kymera Therapeutics$134.68 High Price Target$180.00 Low Price Target$97.00 Potential Upside/Downside+17.3%Consensus RatingModerate Buy Rating Score (0-4)2.89 Research Coverage27 Analysts Profitability EPS (Trailing Twelve Months)($3.24) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$311.35 million Net Margins-285.33% Pretax Margin-285.33% Return on Equity-21.22% Return on Assets-19.21% Debt Debt-to-Equity RatioN/A Current Ratio10.34 Quick Ratio10.34 Sales & Book Value Annual Sales$39.21 million Price / Sales243.53 Cash FlowN/A Price / Cash FlowN/A Book Value$19.42 per share Price / Book5.91Miscellaneous Outstanding Shares83,150,000Free Float69,863,000Market Cap$9.55 billion OptionableOptionable Beta1.98 Social Links 7 Best Space Stocks to Own in 2026The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.Get This Free Report This page (NASDAQ:KYMR) was last updated on 10/26/2026 by MarketBeat.com Staff. From Our Partners80 Days Until America's Rare Earth Supply Chain ShiftChina controls more than 90% of global rare earth alloy production, leverage it is using to restrict exports t...The Tomorrow Investor | SponsoredWould Anthropic IPO Burst the Bubble?The biggest IPO in history is likely just weeks away… Anthropic, the company behind Claude AI, is rumoured ...Crypto 101 Media | SponsoredThe investigation Porter spent tens of thousands to documentPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...Porter & Company | SponsoredHe turned $12K into $1.65M without touching Apple or TeslaTim Sykes turned $12,415 in gift money into more than $1.65 million before graduating college, without trading...Tim Sykes | SponsoredLast call for your free 0DTE reportThe 0DTE Game Plan lays out a simple 3-step framework for trading same-day options: Plan it, profit from it, p...Profits Run | SponsoredWhy Gerardo Del Real says wait before buying uranium stocksGerardo Del Real is calling it the Third Convergence Event, a new catalyst hitting the uranium market that he ...Digest Publishing | SponsoredElon Musk’s Hushed FCC Filing. Dec 8th.Elon Musk quietly filed a document with the federal government tied to artificial intelligence, one of the lar...Paradigm Press | SponsoredHere’s Why Trump Won’t End The Iran WarTrump has called an Iran deal close 38 times since the war began, yet the fighting keeps flaring back up. O...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Kymera Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Kymera Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
